Conversely, therapies that are currently used in other indications to block Treg cell function such as anti-CTLA-4 and anti-PD-1 antibodies in cancer116 may predispose patients to allergic diseases by inhibiting and destabilizing Treg cells, especially iTreg cells. Here, CTLA4 is linked to allergic disease.